Biomica CSO to Present at the ECCO 2023 Annual Meeting in Copenhagen between March 1-4, 2023

Biomica, a clinical-stage biopharmaceutical company and subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced its participation in the 2023 ECCO Annual Meeting in Copenhagen, Denmark, from March 1 to 4, 2023.

Rhea-AI Summary

Biomica, a clinical-stage biopharmaceutical company and subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced its participation in the 2023 ECCO Annual Meeting in Copenhagen, Denmark, from March 1 to 4, 2023. The conference focuses on advancements in Inflammatory Bowel Diseases (IBD). Professor Yehuda Ringel, Biomica's CSO, will present a poster titled "Anti-inflammatory Effect and Mechanism of Action of BMC333" during the conference on March 3, 2023. The poster will be accessible until June 4, 2023, and Professor Ringel is available for one-on-one meetings throughout the event.

Argus Session date unavailable

+4.07% session move Open Argus

Details

News Market Reaction – EVGN

The recorded move for EVGN in the trading session of this news was +4.07%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REHOVOT, Israel, March 1, 2023 /PRNewswire/ -- Biomica, a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting at the 2023 ECCO Annual Meeting taking place in Copenhagen, Denmark from March 1 to 4, 2023.

 

The European Crohn's and Colitis Organization (ECCO) annual congress is an international leading meeting focusing on state-of-the-art clinical approaches and cutting-edge research and advances in Inflammatory Bowel Diseases (IBD).

Professor Yehuda Ringel, Biomica's Chief Scientific Officer (CSO), will be presenting recent data from Biomica's IBD R&D pipeline.

 Biomica's abstract entitled "Anti-inflammatory Effect and Mechanism of Action of BMC333, a Rationally-Designed Live Bacterial Consortium Based on Microbiome Functional Genomic Analysis for Treating IBD", was selected for a poster presentation and Professor Ringel will be presenting on the conference Guided Poster Session on Friday, March 3, 2023 between 12:30 and 13:30. The poster will also be available as an e-Poster on the Virtual Congress Platform until June 4, 2023 (presentation number: P035).

Professor Ringel, will be available for one-on-one meetings throughout the conference, and those interested should be in touch with him directly or with Biomica's investor or public relations team.

 

About Biomica Ltd.:

Biomica is a clinical stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing MicroBoost AI tech engine, licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN).

For more information, please visit www.biomicamed.com.

 

About Evogene Ltd.:

Evogene (NASDAQ: EVGN) (TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene's subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by Ag Plenus, medical cannabis products by Canonic and castor varieties, for the biofuel and other industries, by Casterra. 

 

Contact :

Investor Contact:
Kenny Green Email: kenny.green@evogene.com Tel: +1 212 378 8040	Professor Yehuda Ringel Email: Yehuda.Ringel@biomicamed.com

 

Logo - https://mma.prnewswire.com/media/1974949/Biomica.jpg 
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg

 

View original content:https://www.prnewswire.com/news-releases/biomica-cso-to-present-at-the-ecco-2023-annual-meeting-in-copenhagen-between-march-1-4-2023-301760097.html

SOURCE Biomica Ltd.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the focus of the 2023 ECCO Annual Meeting where EVGN is presenting?

The 2023 ECCO Annual Meeting focuses on advancements in Inflammatory Bowel Diseases (IBD).

When will Professor Yehuda Ringel present at the ECCO event?

Professor Yehuda Ringel will present on March 3, 2023, during a Guided Poster Session.

What is the title of Biomica's poster presentation at the ECCO Annual Meeting?

The title is "Anti-inflammatory Effect and Mechanism of Action of BMC333".

How long will the e-Poster from Biomica be available after the ECCO Meeting?

The e-Poster will be available until June 4, 2023.

Who is the Chief Scientific Officer of Biomica presenting at the ECCO meeting?

Professor Yehuda Ringel is the Chief Scientific Officer of Biomica.

What company is Biomica a subsidiary of?

Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN).